These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30926354)

  • 41. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
    Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
    Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.
    Yang Y; Fujita J; Bandoh S; Ohtsuki Y; Yamadori I; Yoshinouchi T; Ishida T
    Clin Exp Immunol; 2002 Apr; 128(1):169-74. PubMed ID: 11982605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Bw4 and Bw6 epitope mismatches on antibody production, acute and chronic rejection, and graft survival in renal allografts.
    Leffell MS; Kraus E; Racusen LC; Ratner LE; Charney D; Zachary AA
    Transplantation; 2001 Aug; 72(3):433-7. PubMed ID: 11502972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vimentin antibody production in transplant patients and immunomodulatory effects of vimentin in-vitro.
    Carter V; Howell WM
    Hum Immunol; 2013 Nov; 74(11):1463-9. PubMed ID: 23777931
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
    Clerkin KJ; Farr MA; Restaino SW; Zorn E; Latif F; Vasilescu ER; Marboe CC; Colombo PC; Mancini DM
    J Heart Lung Transplant; 2017 May; 36(5):540-545. PubMed ID: 27916323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphocyte activation induces cell surface expression of an immunogenic vimentin isoform.
    Bilalic S; Michlmayr A; Gruber V; Buchberger E; Burghuber C; Böhmig GA; Oehler R
    Transpl Immunol; 2012 Oct; 27(2-3):101-6. PubMed ID: 22728585
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion.
    Solgi G; Pourmand G; Mehrsai A; Taherimahmoudi M; Nicknam MH; Ebrahimi Rad MR; Seraji A; Asadpoor A; Ansaripor B; Nikbin B; Amirzargar A
    Iran J Immunol; 2010 Mar; 7(1):18-29. PubMed ID: 20371916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
    Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
    Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts.
    Barr ML; Cohen DJ; Benvenisty AI; Hardy M; Reemtsma K; Rose EA; Marboe CC; D'Agati V; Suciu-Foca N; Reed E
    Transplant Proc; 1993 Feb; 25(1 Pt 1):262-4. PubMed ID: 8438294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction between panel reactive antibodies, auto- and cold reactive antibodies, and a positive B cell cross-match in renal and cardiac allograft survival.
    Creemers P; Brink J; Kahn D
    Clin Transplant; 1997 Apr; 11(2):134-8. PubMed ID: 9113450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells.
    Sumitran-Karuppan S; Tyden G; Reinholt F; Berg U; Moller E
    Transpl Immunol; 1997 Dec; 5(4):321-7. PubMed ID: 9504155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
    Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
    Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.
    Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK
    Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy.
    Martin L; Guignier F; Mousson C; Rageot D; Justrabo E; Rifle G
    Transplantation; 2003 Jul; 76(2):395-400. PubMed ID: 12883199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of Sera of Recipients with Allograft Rejection Indicates That Keratin 1 Is the Target of Anti-Endothelial Antibodies.
    Guo X; Hu J; Luo W; Luo Q; Guo J; Tian F; Ming Y; Zou Y
    J Immunol Res; 2017; 2017():8679841. PubMed ID: 28265584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.
    Michaels PJ; Espejo ML; Kobashigawa J; Alejos JC; Burch C; Takemoto S; Reed EF; Fishbein MC
    J Heart Lung Transplant; 2003 Jan; 22(1):58-69. PubMed ID: 12531414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.